Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors – Endpoints News

5 months right after Bob Bradway, CEO of Amgen, stepped down to the M&A table and bought Five Primary for $ 1.9 billion, adopted by the scaled-down Rodeo acquisition, he is made the decision to make yet another biotech buyout .

This time around, Amgen is paying out $ 900 million in income though also committing to milestones of up to $ 1.6 billion to privately held Teneobio, an antibody drug developer with working experience in enhancement new bispecific and multispecific substances. Also, Amgen cited Teneobios, “T-cell engager platform that extends Amgen’s present leadership placement in bispecific T-cell engagers by giving a differentiated but complementary solution to Amgen’s present Bite system.”

Read through on: Endpoints with a Totally free Subscription

Unlock this tale suitable away and sign up for the 112,900+ biopharma gurus who study endpoints each individual working day – and it is cost-free.

Sign-up LOG IN